Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues
AssigneeArena Pharmaceuticals, Inc.
InventorsZhi-Liang Chu, James N. Leonard
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual.
Claims26
A method of preparing a pharmaceutical composition comprising a G protein-coupled receptor 119 (GPR119) agonist having the effect of a glucose-dependent insulinotropic peptide (GIP) secretagogue, the method comprising:
- (a) administering a GPR119 agonist to a mammal;
- and
- (b) determining whether the GPR119 agonist increases a blood GIP level in the mammal,
- wherein the ability of the GPR119 agonist to increase a blood GIP level in the mammal is indicative of the agonist being a GIP secretagogue;
- and
- (c) formulating the GPR119 agonist having the effect of a GIP secretagogue with a pharmaceutically acceptable carrier.
A method of preparing a pharmaceutical composition comprising a GPR119 agonist having the effect of a GIP secretagogue, the GPR119 agonist having been administered to a mammal and determined to increase a blood GIP level in a biological sample obtained from the mammal, wherein the ability of GPR119 agonist to increase a blood GIP level in the biological sample is indicative of the agonist being a GIP secretagogue, the method comprising formulating the GPR119 agonist having the effect of a GIP secretagogue with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.